Products

EyeArt
Eyenuk
Ophthalmology AI

See all 1 product →

About Eyenuk

Eyenuk, Inc. is a global artificial intelligence (AI) medical technology and services company dedicated to preventing blindness and accelerating the transition to predictive and preventative healthcare. The company specializes in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Their mission is to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases.

Their flagship product, the EyeArt® AI Eye Screening System, is designed to make in-clinic, real-time diabetic retinopathy (DR) screening possible for primary care practices, diabetes centers, and optometric offices. The system autonomously analyzes retinal images to detect the presence and extent of lesions, and determines the level of disease based on internationally recognized clinical scales, providing results in under 60 seconds without the need for an eyecare specialist on-site.

Beyond diabetic retinopathy, Eyenuk is developing a portfolio of AI-based products to address other critical eye and systemic diseases. Their innovation pipeline includes solutions for age-related macular degeneration (AMD), glaucoma, stroke risk, cardiovascular risk, and Alzheimer’s disease, leveraging retinal imaging as a window into overall health. The company aims to expand access to crucial screenings, improve patient compliance, and enable early intervention to save sight and potentially impact the management of other chronic conditions.

Focus Areas

Diabetic Retinopathy Age-related Macular Degeneration Glaucoma AI Eye Screening Predictive Biomarkers Digital Health Artificial Intelligence Medical Imaging

Business Intelligence

TechnologyCloud-based AI platform for autonomous disease detection, risk assessment, and disease surveillance, utilizing deep-learning algorithms and real-time image quality feedback. Integrates with EHR systems and multiple retinal camera models.

What Physicians Need to Know

Diabetic Retinopathy (DR)
Eyenuk's flagship EyeArtu00ae AI Eye Screening System provides autonomous detection of more than mild and vision-threatening diabetic retinopathy. It is FDA-cleared and has demonstrated high real-world sensitivity (96% for more than mild DR and 97% for vision-threatening DR) and specificity (88% for more than mild DR and 90% for vision-threatening DR). The system enables immediate, on-site screening and generates reports in under 60 seconds, often without the need for pupil dilation.
Age-related Macular Degeneration (AMD)
The EyeArt system has received CE marking as a Class IIb medical device in the European Union for the autonomous detection of Age-related Macular Degeneration (AMD). This allows for automated screening, grading, and reporting of AMD from a single exam, making screening more accessible.
Glaucomatous Optic Nerve Damage
Eyenuk's EyeArt system also holds CE marking as a Class IIb medical device in the European Union for the autonomous detection of glaucomatous optic nerve damage. This enables automated screening, grading, and reporting for glaucoma at the point-of-care.
AI Eye Screening
Eyenuk is a leader in real-world AI Eye Screeningu2122, offering autonomous disease detection. Their EyeArt system is the world's most-validated AI screening tool, tested on over half a million patient visits globally with over two million images. It integrates deep learning and image analysis algorithms to provide fast, accurate, and consistent results.
AI Predictive Biomarkers
Eyenuk is developing AI Predictive Biomarkersu2122 for risk assessment and disease surveillance. Their EyeMarku2122 product is designed to automatically and accurately track retinopathy progression from visit to visit, providing valuable information beyond a simple positive/negative assessment. They are also researching the use of retinal images for predicting stroke risk, cardiovascular risk, and Alzheimer's disease.
Stroke Risk & Cardiovascular Risk
Eyenuk is actively developing AI Predictive Biomarkers for assessing stroke and cardiovascular risk through retinal image analysis. The eye offers a non-invasive window into the central nervous system and vascular health, allowing for the detection of microvasculature issues that may indicate broader systemic problems.
Alzheimer's Disease
Eyenuk is involved in research, including a National Health Institute-funded study with Mayo Clinic, to explore the potential for predicting Alzheimer's disease through AI analysis of retinal images. They are developing AI Predictive Biomarkers for risk assessment and surveillance of Alzheimer's disease.
Physician Tip

Eyenuk's technology, particularly the EyeArt system, empowers physicians and general practitioners to provide comprehensive diabetes care by enabling in-clinic, real-time eye screenings without needing an on-site eye care specialist. This improves patient compliance with annual screenings, reduces unnecessary referrals, and allows ophthalmologists to focus on higher-yield procedures. The system delivers actionable, easy-to-read, ICD-10 compliant reports quickly, enhancing patient education and potentially improving HEDIS measures and CMS 5-Star quality ratings. Its autonomous nature and high accuracy, even with non-dilated images, make it a valuable tool for early detection and prevention of vision loss, addressing the shortage of eye care providers.

Eyenuk's EyeArt system is designed for seamless integration into clinical workflows. It is compatible with multiple fundus cameras from different manufacturers, including Canon CR-2 AF, Canon CR-2 Plus AF, and Topcon NW400, and Optomed Aurora. The system can also integrate with picture archiving and communications/electronic medical records (PACS/EMR) systems. Eyenuk supports federal efforts to promote interoperable standards for ophthalmic imaging data.

Products by Eyenuk

1 product in the directory

EyeArt
Eyenuk
Ophthalmology AI

Videos

News, demos, and interviews about Eyenuk.

Loading videos...

Videos load interactively. If none appear, search YouTube for Eyenuk →

View all on YouTube

No press coverage or publications on file yet. Know of some? Suggest an edit →

Frequently Asked Questions

Eyenuk's EyeArt AI Eye Screening System is FDA-cleared in the U.S. for the autonomous detection of both more than mild and vision-threatening Diabetic Retinopathy (DR). In the European Union, EyeArt holds CE marking under MDR Class IIb for the autonomous detection of Diabetic Retinopathy, Age-related Macular Degeneration (AMD), and Glaucomatous Optic Nerve Damage from a single exam.
Eyenuk is actively developing AI Predictive Biomarkersu2122 designed for risk assessment and disease surveillance across a multitude of systemic conditions. By analyzing retinal images, the technology aims to provide insights into risks for stroke, cardiovascular conditions, and Alzheimer's disease, with ongoing research including collaborations like an NIH-funded study with Mayo Clinic for Alzheimer's prediction.
The EyeArt system is FDA-cleared in the U.S. and has CE marking in the EU, along with a Health Canada license for Diabetic Retinopathy. It is designed to be compliant with HIPAA and GDPR for patient data privacy and security, and has undergone independent audits for SOC2 Type II and HIPAA compliance.
Yes, the EyeArt AI system is reimbursable by Medicare in the U.S. under the Category 1 Current Procedural Terminology (CPT) code 92229. CMS has established a national payment rate for this code, estimated at approximately $45.69 for the physician fee, though actual amounts may vary by geographic locality. For specific pricing details, Eyenuk encourages direct contact.
Eyenuk's EyeArt system is designed for ease of use, allowing nurses or technicians to operate it with minimal training. They offer an online web portal for existing users to access support, tutorials, and manuals, with additional assistance available via a contact form. The system also features a RESTful API for seamless integration with existing Electronic Health Record (EHR) and Picture Archival and Communication Systems (PACS).
Eyenuk is a global AI digital health company with its EyeArt system in clinical use across North America, Europe, Africa, India, and Latin America, spanning over 18 countries. The company secured $26 million in Series A funding in October 2022, bringing its total funding to over $43 million, with investors including AXA IM Alts, demonstrating strong financial backing and stability. Eyenuk also engages in strategic partnerships, such as with the American Academy of Ophthalmology for underserved communities and national health systems like Norway's.
The EyeArt system significantly enhances clinical workflow by providing automated, real-time screening for eye diseases like diabetic retinopathy in a single office visit, often without the need for eye dilation. It allows non-specialist staff to capture images and generates easy-to-read reports in under 60 seconds, enabling immediate identification of patients needing specialist referral. This improves patient compliance, reduces costs, and helps close care gaps in primary care.

Related Companies

VUNO is a leading South Korean medical AI company that develops and commercializes deep learning-based medical AI solutions. The company’s core mission is to leverage AI technology to enhance healthcare by enabling early disease detection and prevention, ultimately aiming to improve the quality of life for patients. VUNO’s solutions analyze a wide range of medical […]

RetiVue is a healthcare AI company specializing in novel widefield retinal camera technology and eye care cloud services. Their mission is to prevent blindness in underserved and medically at-risk populations by providing affordable, high-definition retinal imaging solutions. The company’s flagship product, the EntireEye Imaging System, offers non-contact, non-mydriatic, high-definition image capture with up to a […]

AI Optics is a healthcare AI company dedicated to transforming point-of-care diagnostics through innovative AI-powered retinal screening technology. The company develops portable hardware and AI-based software to bring eye screening out of specialist offices and into primary care and retail health settings, aiming to increase access to eye screening and empower healthcare professionals to make […]

Thirona is a Dutch MedTech company specializing in artificial intelligence (AI) for advanced medical image analysis, primarily focusing on thoracic CT scans, chest X-rays, and retinal images. Founded by scientists Eva van Rikxoort and Bram van Ginneken from the Radboud University Medical Center, Thirona aims to bridge the gap between academic advancements in medical image […]

Google Health, an initiative (formerly a division) of Google, aims to leverage Google’s technology, particularly AI, to improve health outcomes globally. The company focuses on developing AI-powered tools and products to enhance the efficiency of healthcare workflows, reduce administrative burdens, accelerate innovation, and decrease costs. For physicians, this translates to tools like Google Care Studio, […]

Optivate is a healthcare AI company that provides a unified ophthalmology EHR platform designed to streamline workflows, reduce administrative burden, and improve patient care. The platform is purpose-built for ophthalmology and eye care practices, rather than being adapted from generic or multi-specialty systems. It integrates clinical care, practice management, revenue cycle, patient engagement, and optical […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.